Floatz logo

AEX4089DC1

Small Cell Carcinoma

MacroGenicsantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Small Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Vinorelbine
EpicentRx, Inc.
Phase 2BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
EpicentRx, Inc.
Phase 2BB
Pembrolizumab
Thomas Jefferson University
Phase 2BB
Carboplatin
SystImmune Inc.
Phase 3BB

View all 22 →

Same molecule, other indications

AEX4089DC1 is also rated in:

Androgen-Independent Prostatic CancerDormant
CCC
Indicative ·
53 / 100
View asset →
small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
Anal NeoplasmDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →